Investors with an interest in Financial - Investment Management stocks have likely encountered both Affiliated Managers Group (AMG) and Ares Management (ARES) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies wit ...

Investors interested in Medical Services stocks are likely familiar with BrightSpring Health Services, Inc. (BTSG) and Medpace (MEDP) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our S ...

Investors interested in stocks from the Paper and Related Products sector have probably already heard of Suzano S.A. Sponsored ADR (SUZ) and Klabin SA (KLBAY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Ra ...

Investors with an interest in Waste Removal Services stocks have likely encountered both H20 (HTO) and Waste Management (WM) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revi ...

Core Viewpoint - The comparison between Progyny (PGNY) and HealthEquity (HQY) indicates that PGNY is currently more attractive to value investors due to its stronger earnings estimate revisions and better valuation metrics [1][3][7]. Valuation Metrics - PGNY has a forward P/E ratio of 13.82, while HQY has a forward P/E of 25.75, suggesting PGNY is undervalued compared to HQY [5]. - PGNY's PEG ratio is 0.83, indicating a more favorable valuation relative to its expected earnings growth, whereas HQY's PEG ratio is 1.19 [5]. - The P/B ratio for PGNY is 3.75, compared to HQY's P/B of 3.99, further supporting PGNY's superior valuation metrics [6]. Analyst Outlook - PGNY holds a Zacks Rank of 2 (Buy), reflecting a positive earnings estimate revision trend, while HQY has a Zacks Rank of 3 (Hold), indicating a less favorable outlook [3][7]. - The stronger estimate revision activity for PGNY suggests a more optimistic analyst outlook compared to HQY [7]. Value Grades - PGNY has been assigned a Value grade of B, while HQY has a Value grade of D, highlighting PGNY's better performance in key valuation metrics [6].

Core Insights - Keros Therapeutics, Inc. (KROS) is currently more attractive to value investors compared to argenex SE (ARGX) based on various financial metrics and analyst outlooks [1][3][7] Valuation Metrics - KROS has a forward P/E ratio of 10.55, significantly lower than ARGX's forward P/E of 50.00, indicating KROS is potentially undervalued [5] - The PEG ratio for KROS is 0.45, while ARGX has a PEG ratio of 0.89, suggesting KROS offers better value relative to its expected earnings growth [5] - KROS's P/B ratio stands at 0.7, compared to ARGX's P/B of 8.58, further highlighting KROS's undervaluation [6] Analyst Outlook - KROS holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings estimate revision trend, while ARGX has a Zacks Rank of 3 (Hold) [3] - KROS's stronger estimate revision activity and more attractive valuation metrics suggest it is the superior option for value investors at this time [7]

Core Viewpoint - The article compares Federated Hermes (FHI) and SEI Investments (SEIC) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - FHI has a Zacks Rank of 1 (Strong Buy), while SEIC has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for FHI [3] - The Zacks Rank emphasizes stocks with positive revisions to earnings estimates, suggesting an improving earnings outlook for FHI [3] Group 2: Valuation Metrics - FHI has a forward P/E ratio of 10.35, compared to SEIC's forward P/E of 14.82, indicating that FHI may be undervalued [5] - FHI's PEG ratio is 0.53, while SEIC's PEG ratio is 1.23, further suggesting that FHI is a better value option when considering expected earnings growth [5] - FHI's P/B ratio is 3.35, whereas SEIC's P/B ratio is 4.22, reinforcing the notion that FHI is more attractively priced [6] Group 3: Value Grades - FHI has earned a Value grade of B, while SEIC has a Value grade of C, indicating that FHI is viewed as a superior value investment based on various valuation metrics [6]

Core Viewpoint - The article compares Banco Santander (SAN) and Toronto-Dominion Bank (TD) to determine which stock is more attractive to value investors, highlighting that SAN currently shows stronger potential based on various valuation metrics [1][3]. Valuation Metrics - Banco Santander has a forward P/E ratio of 9.64, while Toronto-Dominion Bank has a forward P/E of 13.78, indicating that SAN is potentially undervalued compared to TD [5]. - The PEG ratio for SAN is 0.66, suggesting a favorable valuation relative to its expected earnings growth, whereas TD's PEG ratio is 1.66, indicating a higher valuation relative to growth expectations [5]. - SAN's P/B ratio is 1.17, compared to TD's P/B of 1.66, further supporting the notion that SAN is undervalued [6]. Earnings Outlook - SAN is currently experiencing an improving earnings outlook, which contributes to its strong Zacks Rank of 1 (Strong Buy), while TD holds a Zacks Rank of 2 (Buy) [3][7].

Core Insights - The article compares Allstate (ALL) and W.R. Berkley (WRB) to determine which stock offers better value for investors [1] Valuation Metrics - Allstate has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while W.R. Berkley has a Zacks Rank of 3 (Hold) [3] - Allstate's forward P/E ratio is 8.68, significantly lower than W.R. Berkley's forward P/E of 18.01 [5] - The PEG ratio for Allstate is 0.74, suggesting it is undervalued relative to its expected earnings growth, compared to W.R. Berkley's PEG ratio of 2.63 [5] - Allstate's P/B ratio is 2.4, while W.R. Berkley's P/B ratio is 3.11, further indicating Allstate's relative undervaluation [6] - Allstate has a Value grade of A, whereas W.R. Berkley has a Value grade of C, highlighting Allstate's stronger value proposition [6] Earnings Outlook - Allstate is experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model [7]

Core Viewpoint - Cognizant (CTSH) is currently viewed as a better value opportunity compared to Infosys (INFY) based on earnings outlook and valuation metrics [1][3]. Valuation Metrics - CTSH has a forward P/E ratio of 12.94, while INFY has a forward P/E of 21.19 [5]. - CTSH's PEG ratio is 1.39, indicating a more favorable growth expectation compared to INFY's PEG ratio of 2.80 [5]. - CTSH has a P/B ratio of 2.13, significantly lower than INFY's P/B of 6.13, suggesting that CTSH is undervalued relative to its book value [6]. Earnings Outlook - CTSH has experienced stronger estimate revision activity, indicating a more positive earnings outlook compared to INFY [7]. - The Zacks Rank for CTSH is 2 (Buy), while INFY holds a Zacks Rank of 4 (Sell), further supporting the conclusion that CTSH is the superior option for value investors [3][7]. Value Grades - CTSH has earned a Value grade of A, while INFY has a Value grade of C, reflecting the relative attractiveness of their valuations [6].